NextCure (NASDAQ:NXTC) Major Shareholder Acquires $1,443,750.50 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc acquired 292,850 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were bought at an average cost of $4.93 per share, for a total transaction of $1,443,750.50. Following the acquisition, the insider directly owned 686,116 shares in the company, valued at $3,382,551.88. This represents a 74.47% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Friday, July 31st, Adar1 Capital Management, Llc bought 36,303 shares of NextCure stock. The shares were bought at an average cost of $4.94 per share, with a total value of $179,336.82.
• On Wednesday, July 29th, Adar1 Capital Management, Llc bought 3,410 shares of NextCure stock. The shares were bought at an average cost of $5.00 per share, with a total value of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The shares were bought at an average price of $4.95 per share, for a total transaction of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $38,990.00.

NextCure Trading Down 9.2%

NXTC stock opened at $5.25 on Thursday. The firm has a 50 day moving average of $3.38 and a 200-day moving average of $8.48. NextCure, Inc. has a 12 month low of $1.55 and a 12 month high of $15.74. The firm has a market capitalization of $18.95 million, a P/E ratio of -0.31 and a beta of 1.27.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, beating the consensus estimate of ($2.10) by $0.23. Sell-side analysts predict that NextCure, Inc. will post -7.89 EPS for the current year.

Analysts Set New Price Targets

NXTC has been the topic of several research analyst reports. Wall Street Zen cut shares of NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of NextCure in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, NextCure presently has an average rating of “Hold” and a consensus target price of $19.00.

Institutional Trading of NextCure

Hedge funds have recently made changes to their positions in the stock. Cable Car Capital LP increased its stake in NextCure by 13.1% in the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after purchasing an additional 55,412 shares during the last quarter. Ikarian Capital LLC bought a new stake in NextCure during the fourth quarter worth about $3,382,000. Squadron Capital Management LLC purchased a new position in shares of NextCure in the 4th quarter worth about $3,363,000. Finally, Exome Asset Management LLC bought a new position in shares of NextCure during the 4th quarter valued at about $2,341,000. 42.65% of the stock is owned by institutional investors.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.